16. 1.1.1.1.1.1 Phase II enzalutamide resistance run in cohort ONLY Patients with histologically confirmed adenocarcinoma of the prostate that have progressed after at least 1 line of taxane based therapy and progressed on enzalutamide treatment (having received a minimum of 12 weeks enzalutamide) more than 6 months prior to entry (day of starting IMP). Prior treatment with abiraterone is not an exclusion criteria.